Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions (BALI)
Primary Purpose
Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease
Status
Recruiting
Phase
Not Applicable
Locations
International
Study Type
Interventional
Intervention
Lithoplasty
Conventional
Sponsored by
About this trial
This is an interventional treatment trial for Percutaneous Coronary Intervention
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years and < 90 years
- Stable coronary heart disease or non-ST elevation acute coronary syndrome
- PCI planned in severely calcified, non-occluded, de-novo lesion in native vessel. Definition of severe calcifications (minimum 1 of 3 (i-iii)); i. Angiography: Radioopacities of the vessel wall visible on cine images before contrast injection on both sides of the vessel lumen in more than one projection. ii. OCT (before lesion preparation): Maximum calcium 1) angle >180 degrees AND 2) thickness 0.5mm, AND 3) longitudinal length >5m m. iii. IVUS (before lesion preparation): Maximum calcium angle >270 degrees.
- Functional evidence of ischemia (non-invasive stress test or fractional flow reserve) in the target vessel territory or stenosis ≥ 90% by visual estimate
- Target vessel reference diameter visually estimated at 2.5-4 mm with ability to pass a 0.014" guidewire across lesion
- Ability to tolerate dual antiplatelet therapy
- Informed consent
Angiographic exclusion criteria:
- Unprotected left main stenosis
- Chronic total occlusion
- Severely calcified bifurcated lesion with expected need to use two stent technique
- Coronary artery dissection
Clinical exclusion criteria
- ST-segment elevation acute myocardial infarction
- Planned later revascularization in non-study lesions
- Planned cardiovascular intervention within 30 days after study intervention
- Clinical instability including decompensated heart disease
- Life expectancy of less than 1 year
- Active peptid ulcer or upper gastrointestinal bleeding within 6 months
- Ongoing systemic infection
Paraclinical exclusion criteria
- Left ventricular ejection fraction <35 %
- Renal function with eGFR <30 mL/min
- Pregnant or nursing
Sites / Locations
- University Hospital LeuvenRecruiting
- Gentofte University HospitalRecruiting
- Aalborg University HospitalRecruiting
- Aarhus University Hospital SkejbyRecruiting
- RigshospitaletRecruiting
- Odense University HospitalRecruiting
- Zealand University Hospital, Roskilde SygehusRecruiting
- North-Estonia Medical CenterRecruiting
- Trondheim University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
Lithoplasty lesion preparation
Conventional lesion preparation
Arm Description
Balloon lithoplasty will be used as lesion preparation.
Conventional and modified balloons will be used as lesion preparation.
Outcomes
Primary Outcome Measures
Number of patients with combined outcome of strategy failure
Failed stent delivery, residual area stenosis ≥ 20% (OCT-assessed) after PCI, or target vessel failure.
Residual area stenosis will be defined as [minimal stent area/reference area]. The reference area will be calculated by averaging the proximal and distal reference areas, which will be determined by measuring the lumen contours on most healthy-looking frame of the final OCT in the 0-5 mm edge segments. If a reference cannot be measured on the final OCT, it will be measured on a pre-stent OCT or by using quantitative coronary angiography if pre-stent OCT is unavailable. Target vessel failure will be defined as cardiac death, target vessel-related myocardial infarction, or clinically driven target vessel revascularization).
Secondary Outcome Measures
Number of patients with composite and components of in-hospital major adverse cardiac events (MACE)
Cardiac death, Any myocardial infarction, Stroke
Number of patients with in-hospital procedure-related adverse events
Periprocedural myocardial infarction, Coronary dissection (beyond intended by lesion preparation), Coronary perforation/rupture, Coronary abrupt closure, Coronary low flow/no flow, Arrhythmia
Number of patients with components of target vessel failure
Cardiac death, Target vessel-related myocardial infarction, Clinically driven target vessel revascularization
Number of patients with components of the primary outcome
Failed stent delivery, Residual area stenosis >20% (OCT-assessed) after PCI, Target vessel failure
OCT outcomes at index procedure
Core-lab quantification of: Stent expansion, Stent malapposition, Quantified evidence of calcium disruption
OCT outcomes at 1 year procedure
Core-lab quantification of: In-stent late lumen loss, In-segment late lumen loss, In-segment re-stenosis, Stent malapposition, Quantified evidence of calcium disruption,
Number of patients with composite and components of major adverse cardiac events (MACE)
Cardiac death, Any myocardial infarction, Stroke
Number of patients with primary endpoint and its composites at 2 years
Failed stent delivery, residual area stenosis ≥ 20% (OCT-assessed) after PCI, or target vessel failure
Number of patients with composite of target vessel failure and its components at 2 years
Cardiac death, Target vessel-related myocardial infarction, Clinically driven target vessel revascularization
Overall mortality at 1 year
Death due to any cause
Overall mortality at 2 years
Death due to any cause
Full Information
NCT ID
NCT04253171
First Posted
January 28, 2020
Last Updated
May 3, 2023
Sponsor
Herlev and Gentofte Hospital
Collaborators
Abbott
1. Study Identification
Unique Protocol Identification Number
NCT04253171
Brief Title
Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions
Acronym
BALI
Official Title
Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions Before Stent Implantation - a Nationwide Randomized Trial (BALI)
Study Type
Interventional
2. Study Status
Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 29, 2020 (Actual)
Primary Completion Date
January 1, 2024 (Anticipated)
Study Completion Date
January 1, 2025 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Herlev and Gentofte Hospital
Collaborators
Abbott
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Severely calcified coronary stenoses are difficult to treat with percutaneous coronary intervention (PCI) using current techniques and there is little specific evidence on how to best treat these cases. It is hypothesized that balloon lithoplasty is superior to conventional balloons for lesion preparation of severely calcified coronary lesions before stent implantation in terms of procedural failure and 1-year target vessel failure.
Detailed Description
Severely calcified coronary stenoses are difficult to treat with percutaneous coronary intervention (PCI) using current techniques. Severe calcifications make it difficult to sufficiently prepare lesions before stenting, to advance stents, and to achieve full stent expansion. There is increased risk of vessel dissection and perforation with angioplasty on severely calcified lesions, and long-term outcomes of PCI are adversely affected. Because severely calcified lesions are often excluded from interventional studies, there is little specific evidence on how to best treat these cases. Only a few randomized studies have specifically explored this question, focusing on the use of rotational atherectomy
Recently, the technique of balloon-based lithoplasty was made commercially available. With this technique, calcifications are cracked with the creation of high-frequency pressure oscillations in a special angioplasty balloon. Standard techniques are used to deliver and dilate the balloon. The method was developed for treatment of otherwise non-dilatable lesions, and first reported results have been encouraging. The lithoplasty device used in the current study (Shockwave IVL, Shockwave Medical, CA, USA) has received CE-mark and post-approval safety has recently been confirmed for treatment of severely calcified coronary lesions in patients.
Besides obvious benefits in non-dilatable lesions for which interventional cardiologists have few other options, it is possible this technique could change the way all severely calcified lesions are treated. Balloon lithoplasty could theoretically crack plates of calcium in the vessel wall in an orderly fashion, which could lead to safer and quicker preparation of severely calcified lesions. Furthermore, a better softening of vessel wall calcium could allow full and symmetric expansion of coronary stents, which could lead to better long-term stent patency.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Percutaneous Coronary Intervention, Coronary Artery Calcification, Coronary Artery Disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Investigator-initiated 1:1 randomized, controlled, unblinded, nationwide, superiority trial.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Lithoplasty lesion preparation
Arm Type
Active Comparator
Arm Description
Balloon lithoplasty will be used as lesion preparation.
Arm Title
Conventional lesion preparation
Arm Type
Active Comparator
Arm Description
Conventional and modified balloons will be used as lesion preparation.
Intervention Type
Device
Intervention Name(s)
Lithoplasty
Other Intervention Name(s)
Shockwave, Lithotripsy
Intervention Description
The lithoplasty balloon should be utilized as early as possible. If it is necessary for passage of the lithoplasty balloon, the lesion may first be predilated with an undersized conventional balloon, non-compliant or semi-compliant. If passage of the lithoplasty balloon is still not possible, it is recommended to perform rotational atherectomy with a small burr size.
The lithoplasty balloon is sized 1:1 to reference diameter. Lithoplasty is performed with the balloon dilated at 4 atmospheres, and 10 shocks are delivered, after which the balloon is expanded to 6 atmospheres for 30 seconds, and then deflated. Up to 8 series of balloon expansion/deflation can be delivered in this manner if necessary, and several balloons may be used for long lesions.
Intervention Type
Device
Intervention Name(s)
Conventional
Intervention Description
Lesion preparation is performed starting with conventional balloons, non-compliant or semi-compliant. Unless fully satisfactory dilatation is achieved with conventional balloons, it is recommended to also use modified balloons (scoring balloons, cutting balloons). If balloons cannot be passed or if dilatation is inadequate, the lesion may first be predilated with an undersized conventional, non-compliant, or semi-compliant balloon. If necessary, rotational atherectomy with a small burr size can be used to facilitate adequate balloon preparation.
Primary Outcome Measure Information:
Title
Number of patients with combined outcome of strategy failure
Description
Failed stent delivery, residual area stenosis ≥ 20% (OCT-assessed) after PCI, or target vessel failure.
Residual area stenosis will be defined as [minimal stent area/reference area]. The reference area will be calculated by averaging the proximal and distal reference areas, which will be determined by measuring the lumen contours on most healthy-looking frame of the final OCT in the 0-5 mm edge segments. If a reference cannot be measured on the final OCT, it will be measured on a pre-stent OCT or by using quantitative coronary angiography if pre-stent OCT is unavailable. Target vessel failure will be defined as cardiac death, target vessel-related myocardial infarction, or clinically driven target vessel revascularization).
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Number of patients with composite and components of in-hospital major adverse cardiac events (MACE)
Description
Cardiac death, Any myocardial infarction, Stroke
Time Frame
In-hospital during and immediately after procedure
Title
Number of patients with in-hospital procedure-related adverse events
Description
Periprocedural myocardial infarction, Coronary dissection (beyond intended by lesion preparation), Coronary perforation/rupture, Coronary abrupt closure, Coronary low flow/no flow, Arrhythmia
Time Frame
In-hospital during and immediately after procedure
Title
Number of patients with components of target vessel failure
Description
Cardiac death, Target vessel-related myocardial infarction, Clinically driven target vessel revascularization
Time Frame
1 year
Title
Number of patients with components of the primary outcome
Description
Failed stent delivery, Residual area stenosis >20% (OCT-assessed) after PCI, Target vessel failure
Time Frame
1 year
Title
OCT outcomes at index procedure
Description
Core-lab quantification of: Stent expansion, Stent malapposition, Quantified evidence of calcium disruption
Time Frame
During procedure
Title
OCT outcomes at 1 year procedure
Description
Core-lab quantification of: In-stent late lumen loss, In-segment late lumen loss, In-segment re-stenosis, Stent malapposition, Quantified evidence of calcium disruption,
Time Frame
1 year
Title
Number of patients with composite and components of major adverse cardiac events (MACE)
Description
Cardiac death, Any myocardial infarction, Stroke
Time Frame
1 year
Title
Number of patients with primary endpoint and its composites at 2 years
Description
Failed stent delivery, residual area stenosis ≥ 20% (OCT-assessed) after PCI, or target vessel failure
Time Frame
2 years
Title
Number of patients with composite of target vessel failure and its components at 2 years
Description
Cardiac death, Target vessel-related myocardial infarction, Clinically driven target vessel revascularization
Time Frame
2 years
Title
Overall mortality at 1 year
Description
Death due to any cause
Time Frame
1 year
Title
Overall mortality at 2 years
Description
Death due to any cause
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years and < 90 years
Stable coronary heart disease or non-ST elevation acute coronary syndrome
PCI planned in severely calcified, non-occluded, de-novo lesion in native vessel. Definition of severe calcifications (minimum 1 of 3 (i-iii)); i. Angiography: Radioopacities of the vessel wall visible on cine images before contrast injection on both sides of the vessel lumen in more than one projection. ii. OCT (before lesion preparation): Maximum calcium 1) angle >180 degrees AND 2) thickness 0.5mm, AND 3) longitudinal length >5m m. iii. IVUS (before lesion preparation): Maximum calcium angle >270 degrees.
Functional evidence of ischemia (non-invasive stress test or fractional flow reserve) in the target vessel territory or stenosis ≥ 90% by visual estimate
Target vessel reference diameter visually estimated at 2.5-4 mm with ability to pass a 0.014" guidewire across lesion
Ability to tolerate dual antiplatelet therapy
Informed consent
Angiographic exclusion criteria:
Unprotected left main stenosis
Chronic total occlusion
Severely calcified bifurcated lesion with expected need to use two stent technique
Coronary artery dissection
Clinical exclusion criteria
ST-segment elevation acute myocardial infarction
Planned later revascularization in non-study lesions
Planned cardiovascular intervention within 30 days after study intervention
Clinical instability including decompensated heart disease
Life expectancy of less than 1 year
Active peptid ulcer or upper gastrointestinal bleeding within 6 months
Ongoing systemic infection
Paraclinical exclusion criteria
Left ventricular ejection fraction <35 %
Renal function with eGFR <30 mL/min
Pregnant or nursing
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Niels Thue Olsen, MD, PhD
Phone
+45 38 67 25 60
Email
niels.thue.olsen@regionh.dk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Niels Thue Olsen, MD, PhD
Organizational Affiliation
Herlev and Gentofte Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
University Hospital Leuven
City
Leuven
Country
Belgium
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Johan Bennett
Facility Name
Gentofte University Hospital
City
Gentofte
State/Province
Copenhagen
ZIP/Postal Code
2900
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Niels Thue Olsen, MD, PhD
Phone
+45 38 67 25 60
Email
niels.thue.olsen@regionh.dk
Facility Name
Aalborg University Hospital
City
Aalborg
ZIP/Postal Code
9100
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bent Raungaard, MD, PhD
Facility Name
Aarhus University Hospital Skejby
City
Aarhus
ZIP/Postal Code
8200
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Evald Christiansen, MD, PhD
Facility Name
Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Thomas Engstrøm, Professor
Facility Name
Odense University Hospital
City
Odense
ZIP/Postal Code
5000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Karsten Veien, MD
Facility Name
Zealand University Hospital, Roskilde Sygehus
City
Roskilde
ZIP/Postal Code
4000
Country
Denmark
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Henning Kelbæk, MD, PhD
Facility Name
North-Estonia Medical Center
City
Tallinn
Country
Estonia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Peep Laanmets
Facility Name
Trondheim University Hospital
City
Trondheim
Country
Norway
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ola Kleveland
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Data will be shared by request.
IPD Sharing Time Frame
Within 1 year of study completion.
IPD Sharing Access Criteria
Requests for access will be reviewed by the Steering Committee. A Data Access Agreement will be needed for access.
Learn more about this trial
Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions
We'll reach out to this number within 24 hrs